Maralixibat for the treatment of <scp>PFIC</scp> : <scp>Long‐term</scp> , <scp>IBAT</scp> inhibition in an <scp>open‐label</scp> , Phase 2 study-Reference-Cited by-同舟云学术

Maralixibat for the treatment of PFIC : Long‐term , IBAT inhibition in an open‐label , Phase 2 study

Published:2022-05-04 Issue:9 Volume:6 Page:2379-2390
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:Hepatology Communications

Author:

Loomes Kathleen M.¹²,Squires Robert H.³⁴,Kelly Deirdre⁵⁶,Rajwal Sanjay⁷,Soufi Nisreen⁸⁹,Lachaux Alain¹⁰,Jankowska Irena¹¹,Mack Cara¹²,Setchell Kenneth D. R.¹³¹⁴,Karthikeyan Palaniswamy⁷,Kennedy Ciara¹⁵,Dorenbaum Alejandro¹⁶,Desai Nirav K.¹⁷,Garner Will¹⁸,Jaecklin Thomas¹⁹,Vig Pamela¹⁸,Miethke Alexander²⁰¹⁴,Thompson Richard J.²¹

Affiliation:

1. Division of Gastroenterology, Hepatology and Nutrition Children's Hospital of Philadelphia Philadelphia Pennsylvania USA

2. Department of Pediatrics Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA

3. Pediatric Gastroenterology, Hepatology, and Nutrition Children's Hospital of Pittsburgh University of Pittsburgh Medical Center Pittsburgh Pennsylvania USA

4. Department of Pediatrics University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA

5. Liver Unit Birmingham Women's and Children's Hospital Birmingham UK

6. University of Birmingham Birmingham UK

7. Leeds Teaching Hospitals NHS Trust Leeds UK

8. Division of Gastroenterology, Hepatology and Nutrition Children's Hospital Los Angeles Los Angeles California USA

9. Department of Pediatrics Keck School of Medicine University of Southern California Los Angeles California USA

10. Hepatology and Nutrition Reference Center for Rare Diseases Children's Hospital of Lyon, HCL, and Claude Bernard Lyon University 1 Lyon France

11. Department of Gastroenterology, Hepatology, Feeding Disorders, and Pediatrics Children's Memorial Health Institute Warsaw Poland

12. Pediatric Gastroenterology, Hepatology, and Nutrition Children's Hospital of Wisconsin, Medical College of Wisconsin Milwaukee Wisconsin USA

13. Division of Pathology and Laboratory Medicine Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA

14. Department of Pediatrics University of Cincinnati College of Medicine Cincinnati Ohio USA

15. Amplyx Pharmaceuticals San Diego California USA

16. Department of Pediatrics Stanford School of Medicine Palo Alto California USA

17. Takeda Pharmaceuticals Cambridge Massachusetts USA

18. Mirum Pharmaceuticals Foster City California USA

19. Mirum Pharmaceuticals Basel Switzerland

20. Division of Gastroenterology, Hepatology, and Nutrition Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA

21. Institute of Liver Studies King's College London London UK

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep4.1980

Reference22 articles.

1. Systematic review of progressive familial intrahepatic cholestasis

2. Progressive familial intrahepatic cholestasis: diagnosis, management, and treatment

3. A Drug Regimen for Progressive Familial Cholestasis Type 2

4. Progressive Familial Intrahepatic Cholestasis

5. Genotype correlates with the natural history of severe bile salt export pump deficiency

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ABC transporters involved in respiratory and cholestatic diseases: From rare to very rare monogenic diseases;Biochemical Pharmacology;2024-11

2. Intracellular Trafficking Defects in Congenital Intestinal and Hepatic Diseases;Traffic;2024-08

3. IBAT inhibitors in pediatric cholestatic liver diseases: Transformation on the horizon?;Hepatology;2024-07-25

4. The gut microbiota-bile acid axis in cholestatic liver disease;Molecular Medicine;2024-07-19

5. Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials;Expert Opinion on Emerging Drugs;2024-07-04